Form 4 Filing for Bicara Therapeutics Inc. - Officer/Director Stock Transaction

This filing details a stock option grant to Kate Haviland, a director at Bicara Therapeutics Inc. The option, for 19,475 shares of Common Stock, was granted on June 9, 2026, with an exercise price of $20.56. The shares underlying the option vest on the earlier of June 9, 2027, or the next Annual Meeting of Stockholders, contingent upon continued service. The option has an expiration date of June 9, 2036. This transaction is reported on Form 4.